Thrombocythemia
6
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Platelet Transfusion in Critically Ill Patients With Thrombocytopenia
Pomalidomide for Myelofibrosis Patients
Primary Thrombocythaemia 1 Trial
Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions